Five years ago, XenoPort (XNPT)
was a $40 stock, but while the biotech sector has enjoyed a strong run
these shares have gone the other way on disappointments over the
restless leg drug Horizant and the clinical failures of arbaclofen
placarbil. Although I don't see a credible path back to $40 anytime
soon, the company's monomethyl fumarate (MMF) prodrug XPS23829 ('829)
does give the company at least a fighting chance of grabbing some of the
billions of dollars in revenue expected for Biogen Idec's (BIIB)
latest blockbuster Tecfidera. While the prospect of capturing some of
Tecfidera's potential sales through competitive pricing or clinical
differentiation is intriguing, investors shouldn't kid themselves about
the risks and uncertainties still in play here.
Read the full article here:
Xenoport Looks To '829 To Restore Its Lost Glory
No comments:
Post a Comment